Research Article Open Access Double-Blind Peer Review

IMPROVING INFECTIOUS DISEASE OUTCOMES THROUGH PUBLIC HEALTH AND BIOSTATISTICS

Chiamaka Uchenna Eze
Published 05 June 2025
Vol. 13, No. 2 (2025)
pp. 1-31
CC BY 4.0
  1. 1
    Chiamaka Uchenna Eze
    Department of Radiography and Radiation Sciences Gregory University, Uturu
    NG

This review explores emerging biostatistical methods, the integration of machine learning (ML) and advanced analytics, and the role of big data and artificial intelligence (AI) in addressing health disparities in public health. It highlights the growing importance of Bayesian models and ML algorithms for predicting infectious disease outcomes and stratifying populations by social determinants of health. The review accentuates the potential of AI in precision public health, with applications ranging from real-time disease surveillance to the development of personalized interventions. However, it also emphasizes the ethical challenges and biases associated with AI and ML, particularly in marginalized populations. Future research recommendations focus on developing ethical frameworks, improving the representativeness of training data, and optimizing the use of real-world evidence (RWE) in public health. By combining traditional biostatistical approaches with modern AIdriven tools, this review outlines a path toward more accurate and equitable health outcome predictions, ultimately contributing to the reduction of health disparities on a global scale.

JournalJournal of Medical Technology and Innovation
ISSN3065-0607
Volume / IssueVol. 13, No. 2 (2025)
Pages1-31
Published05 June 2025
DOI10.5281/zenodo.15599251
Access Open Access
LicenseCC BY 4.0 — reuse with attribution
PublisherKeith Publications
Eze, C. (2025). IMPROVING INFECTIOUS DISEASE OUTCOMES THROUGH PUBLIC HEALTH AND BIOSTATISTICS. Journal of Medical Technology and Innovation, Vol. 13 No. 2, pp. 1-31. DOI: https://doi.org/10.5281/zenodo.15599251

 Submit Your Research to Journal of Medical Technology and Innovation

We invite original research articles, review papers, and case studies. Benefit from rigorous double-blind peer review, rapid decision within 4–8 weeks, DOI for every article, and worldwide open-access distribution.